Performance of HIV assays evaluated, indeterminate result samples included.

α<p>Total number of samples included in the calculations.</p>β<p>95% confidence intervals.</p>δ<p>General population HIV prevalence reported in Cameroon in 2004.</p

Characteristics of the HIV diagnostic assays evaluated as described by manufacturers.

<p>Characteristics of the HIV diagnostic assays evaluated as described by manufacturers.</p

Drug resistance-associated mutations at 12 months of ART.

<p><b>Legend </b><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072680#pone-0072680-t004" target="_blank"><b>table 4</b>:</a> PI: protease inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; HIVDR: HIV Drug Resistance.</p

Overall national ART performance for each EWI.

<p>Overall national ART performance for each EWI.</p

Evaluation of EWIs in each of the 40 surveyed sites during the year 2010.

<p>In <i>“</i><b><i>Bold</i></b><i>”</i>: EWI reaching the required target. NV: Not Validated. NA: Not Available.</p><p><u>EWI</u>: Early Warning Indicator.</p><p><u>EWI₁</u>: Percentage of patients initiated on an appropriate first line ARV drug regimen, following national guidelines (Required target performance: 100%);</p><p><u>EWI₂</u>: Percentage of patient lost to follow-up after 12 months of enrolment to ART (Required target performance: ≤20%);</p><p><u>EWI₃</u>: Percentage of patient retained on appropriate first line ART after 12 month of treatment (Required target performance: ≥70%);</p><p><u>EWI₄</u>: Percentage of patients picking-up their ARV drugs on-time at the pharmacy of the ART site (Required target performance: ≥90%);</p><p><u>EWI₅</u>: Percentage of months without ARV drug shutdown at the pharmacy of the ART site (Required target performance: 100%).</p

Staff/Patient ratio in the overall study population.

<p>Staff/Patient ratio in the overall study population.</p

Socio-demographic and medical data of the study population.

<p><b>Legend </b><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072680#pone-0072680-t001" target="_blank"><b>table 1:</b></a> ART: Antiretroviral therapy; HAART: Highly Active Antiretroviral therapy;</p><p>PMTCT: prevention of mother-to-child transmission; IQR: Interquartile range.</p

HIV drug resistance at enrollment on ART.

<p><b>Legend </b><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0072680#pone-0072680-t002" target="_blank"><b>table 2</b>:</a> PI: protease inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; HAART: highly active antiretroviral therapy; VL: viral load; LTFU: lost to follow-up; NVP: nevirapine; 3TC: lamivudine; AZT: zidovudine; d4T: stavudine; EFV: efavirenz.</p

Virologic outcome at the study endpoint (M12).

<p><u>Legend</u>: NA: not applicable.</p

Prevalence of major NRTI and NNRTI resistance mutations in individuals with transmitted drug resistance.

<p>Absolute and cumulative prevalence of each major nucleoside (NRTI) and nonnucleoside RT Inhibitor (NNRTI) drug-resistance mutation (DRM) in individuals with intermediate or high-level transmitted NRTI or NNRTI resistance from a meta-analysis of 287 studies published between 2000 and 2013 are shown. Low- and middle- income countries include Countries of Sub-Saharan Africa, South / Southeast Asia, and Latin America and Caribbean. Upper-Income Countries: Countries of North America and Europe, and upper-income countries in Southeast Asia. Major NRTI DRMs include those with an HIVDB score ≥30. There were no insertions or deletions between codons 67 and 70. Major NNRTI DRMs include those with an HIVDB score ≥60. Absolute %: number of individuals with DRM / number of individuals with intermediate or high-level transmitted NRTI or NNRTI resistance. Cumulative %: number of individuals with one or more of the preceding major DRMs in the list / number of individuals with intermediate or high-level transmitted NRTI or NNRTI resistance.</p